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Abstract 
Background: In Korea, hepatitis B virus (HBV) infection accounts for approximately 65–75% of HBV‑related diseases, 
such as chronic hepatitis and liver cancer, and mother‑to‑child transmission is presumed to be a major source of the 
infection. To tackle this issue, the Korean government launched the national Perinatal Hepatitis B Prevention Program 
(PHBPP) in 2002. This study analyzed the cost‑effectiveness of the PHBPP with antiviral prophylaxis compared with the 
current PHBPP and/or universal vaccination, as well as identified the optimal strategy to eliminate mother‑to‑child 
transmission of HBV in Korea.
Methods: A decision tree model with the Markov process was developed and simulated over the lifetime of a birth 
cohort in Korea during the year 2014. The current PHBPP providing HBV vaccine and hepatitis B immune globulin to 
neonates born to HBV positive mothers was compared against two other strategies, universal vaccination of HBV and 
PHBPP with antiviral prophylaxis, with respect to their costs and health outcomes. The Korean National Health Insur‑
ance database was investigated to estimate the costs of HBV‑related diseases and utilization of health resources. Costs 
were assessed from the health care system perspective and converted to 2014 US dollars. Health outcome measures 
were quality‑adjusted life years (QALYs) and number of HBV‑related diseases and deaths. Both costs and QALYs were 
discounted at 5%, following the recommendation of the Health Insurance Review & Assessment Service in Korea. 
The incremental cost‑effectiveness ratio (ICER) obtained from the analysis was evaluated using the willingness‑to‑pay 
(WTP) in the Korean society.
Results: PHBPP with antiviral prophylaxis in Korea was cost‑effective compared with the current PHBPP. An intro‑
duction of antiviral prophylaxis to pregnant women with a high viral load of HBV averted 13 HBV‑related deaths per 
100,000 people and saved 82 QALYs in total (ICER: $16,159/QALY).
Conclusions: Considering that WTP in Korea is $29,000, PHBPP with antiviral prophylaxis appears to be a cost‑effec‑
tive strategy. To further decrease the burden of perinatal hepatitis B in Korea, adding antiviral prophylaxis to PHBPP is 
recommended.
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Background
Hepatitis B virus (HBV) is a well-known risk factor for 
liver diseases, including chronic hepatitis, cirrhosis, and 
Hepatocellular Carcinoma (HCC) [1]. In Korea, HBV 
infection accounts for approximately 65–75% of these 
disease incidences; it is recognized as an endemic disease 
of the country [2–4]. To cope with this, the Korean gov-
ernment has begun to focus on the prevention of HBV 
infection by vaccinating newborns.
The prevalence of HBV infection in Korea has declined 
over the past several decades. The peak positive rate of 
hepatitis B surface antigen (HBsAg) in the early 1980s 
was recorded to be 8–9% for males and 5–6% for females 
[5]. Since then, with the development of HBV vaccina-
tion by a domestic pharmaceutical company in 1983, the 
prevalence of HBsAg in the Korean population has been 
decreasing steadily, and the addition of HBV vaccination 
into the National Immunization Program for Children in 
1995 further reduced the HBsAg prevalence in the popu-
lation, especially those under the age of 20  years [2, 6], 
dropping the prevalence by one-third, from 3.9% (1996) 
to 1.3% (1999) within the first 5 years since the inception 
of the program [7].
Currently, mother-to-child transmission is presumed 
to be a major source of HBV infection in Korea [8]. In 
2002, the Korea Centers for Disease Control and Pre-
vention (KCDC) launched the national Perinatal Hepa-
titis B Prevention Program (PHBPP) to tackle the issue 
of mother-to-child transmission of HBV. This program 
consists of an administration of hepatitis B immune 
globulin (HBIG) and HBV vaccine at birth, followed by 
two additional doses of HBV vaccine at 1 month and at 
6 months after birth [9]. High rates of program participa-
tion (approximately 96%) and antibody formation among 
participants (approximately 97%) brought a dramatic 
reduction, up to 3% in vertical transmission of HBV [10]. 
However, considering that the timely administration of 
HBV vaccine and HBIG do not fully prevent the occur-
rence of in utero infection of HBV, neonates born to 
mothers with a high viral load of HBV are still suscepti-
ble to the infection [11]. Thus, to eliminate the risk of in 
utero infection of HBV, an inclusion of antiviral prophy-
laxis in the current PHBPP is recommended to pregnant 
women with a high viral load of HBV [12].
The purpose of this study was to assess the cost-effec-
tiveness of PHBPP with antiviral prophylaxis compared 
with the current PHBPP and/or universal vaccination 
that provides only HBV vaccination within the first 24 h 
of birth. Then, we identified the optimal strategy for elim-
inating mother-to-child transmission of HBV in Korea.
Methods
Three intervention strategies
Three preventive strategies against perinatal HBV infec-
tion were illustrated in our decision tree model (Fig. 1). 
The details of each strategy are as follows.
Fig. 1 Decision analytic model. PHBPP, Perinatal Hepatitis B Prevention Program; HBsAg, Hepatitis B Surface Antigen; TBD, Timely Birth Dose; HBV, 
Hepatitis B Virus; HBIG, Hepatitis B Immune Globulin
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1. Universal vaccination: regardless of the HBsAg status 
of mothers, newborns receive the initial dose of HBV 
vaccine within the 24 h of birth. Those administered 
with the initial dose of the vaccination comply with 
the ordinary schedule of HBV vaccination in Korea, 
which is to receive a vaccination at 0, 1, and 6 months 
[13, 14].
2. Current PHBPP: through antenatal screening, 
HBsAg-positive mothers become subjects to receive 
PHBPP. The post-exposure prophylaxis of HBV, a 
combination of HBIG and HBV vaccine, is provided 
to their newborns right after birth. Infants complet-
ing every schedule of HBV vaccination are eligible to 
undergo antigen and antibody tests, which are paid 
for by the government until they acquire the neces-
sary antibodies to HBV [9].
3. PHBPP with antiviral prophylaxis: after antenatal 
screening, an additional HBV-DNA testing is per-
formed on HBsAg-positive mothers to measure their 
viral load of HBV. Mothers with a high viral load 
(≥  106  copies/mL) are eligible to receive antiviral 
prophylaxis for 4  months, beginning at the 3rd tri-
mester of pregnancy up until 1  month postpartum. 
Subsequent measures, which is equivalent to the cur-
rent PHBPP, are administered to newborns to pre-
vent perinatal HBV infection after birth [15].
Model
The decision analytic model with Markov process was 
constructed to evaluate HBV-related costs and health 
outcomes, as well as quality-adjusted life years (QALYs) 
over the lifetime of the birth cohort in Korea during the 
year 2014 [16]. Each node of the model reflects epide-
miological circumstances of HBV in Korea, such as the 
prevalence of mother’s status for HBV antigen and for 
the high viral load of HBV, in addition to the coverage 
and effectiveness of a particular intervention. The basic 
assumption of the model is that mother-to-child trans-
mission is the only channel of HBV infection for the birth 
cohort, focusing on the preventive effect of intervention 
strategies on perinatal infection of HBV [17].
This model also demonstrates the natural history of 
HBV infection among newborns of HBV-positive moth-
ers via the Markov process (Fig. 2) [18]. In this process, 
there are eight distinct health states that indicate the 
progress of HBV morbidity from the susceptible state 
[17, 19–21] (Not infected/Recovery, Immune tolerance/
Inactive state, Chronic hepatitis, Compensated cirrhosis, 
Decompensated cirrhosis, HCC, Disease-specific death, 
and All-cause death). The Markov process terminates 
either when all newborns reach their death state or age 
100. Each Markov cycle is equivalent to 1  year. A half 
cycle correction was applied to estimate the costs and 
effectiveness [18]. The decision model was built using 
TreeAge Pro 2017 (TreeAge Software, Inc., Williams-
town, MA).
Epidemiological parameters and intervention coverages
We differentiated the prevalence of HBV infection among 
pregnant women into three parts, according to the pres-
ence of HBsAg, hepatitis B envelope antigen (HBeAg), 
and high viral load, because the risk of perinatal infec-
tion is respective to their status of antigen and viral load 
[22]. Due to the lack of national data for the proportion 
of high viral load among HBeAg positive mothers, we 
adopted this information from a Taiwanese study by Wen 
et al., which assessed the risk of perinatal HBV infection 
according to the levels of maternal viral load [23]. The 
risk of perinatal infection varied according to maternal 
HBeAg status, timing of birth dose, and HBIG adminis-
tration [10, 24–31]. Moreover, the result from the meta-
analysis examining the reducing effect of Lamivudine 
on the interruption of in utero transmission of HBV was 
chosen to represent the effect of antiviral prophylaxis 
[32]. This indicated that antiviral prophylaxis using Lami-
vudine may reduce the risk of perinatal infection by half.
The coverages of universal vaccination and current 
PHBPP, 90.7 and 99%, respectively, were considered in 
the model to reflect the real environment surrounding 
the vaccination programs in 2014 [10, 33]. Moreover, 
we assumed that the coverage of PHBPP with antiviral 
prophylaxis may increase to 100%, considering that a 
greater focus is paid to pregnant women enrolled in this 
program. To avoid the overestimation of benefits of the 
antiviral prophylaxis, we conducted a sensitivity analysis 
on its coverage by decreasing up to 50%. The parameters 
on the prevalence of HBV infection among pregnant 
women, risk of perinatal HBV infection, and intervention 
coverages are presented in Table 1 [10, 16, 23–34].
Regarding the long-term progression of neonatal HBV 
infection, annual transition probabilities of health states 
in the Markov model were taken from the economic 
Fig. 2 Markov diagram illustrating natural history of HBV. HBV, Hepa‑
titis B Virus; HCC, hepatocellular carcinoma
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literature on vaccination strategies against HBV infec-
tion [17, 19, 20, 35, 36]. A clinical aspect of perinatal 
HBV infection—the high likelihood of developing to the 
immune tolerance phase among those infected with HBV 
during the perinatal period—was considered [37]. All-
cause mortality was estimated using the life table of the 
cohort born in 2014 [38]. Specific values of the transition 
probabilities are listed in Table 2 [17, 19, 20, 35, 36].
Costs estimations
Costs in this study were evaluated from a healthcare 
system perspective, including intervention program 
costs, direct medical costs, and direct non-medical costs 
[39]. All cost estimates were based on the year 2014, 
and the South Korean Won was converted to US dol-
lars ($1  =  ₩1053.3). Table  3 summarizes the detailed 
information.
To estimate the cost of each intervention, a combined 
approach was applied. In calculating the program cost 
of universal vaccination, a micro-costing method that 
encompassed the coverage of vaccination and its cost 
was used. Conversely, the cost of PHBPP was computed 
with a total budget of the program in 2014 by using a 
gross-costing method [33]. For PHBPP with antiviral 
prophylaxis, both methods—the micro-costing and the 
gross-costing—were incorporated in a way that the per 
capita cost of antiviral therapy and HBV-DNA tests were 
added to the total budget of PHBPP [40, 41].
To obtain information of direct medical and non-
medical costs for patients with HBV-sequelae in Korea, 
we explored National Health Insurance Claims Data-
base (NHICD) [42]. NHICD is managed by the National 
Health Insurance Service (NHIS), and contains infor-
mation of the entire Korean population regarding their 
healthcare costs and utilizations (inpatient, outpatient, 
and pharmaceutical) within its insurance benefits pack-
age. For this study, we acquired the insurance claims 
dataset, including information of the entire Korean 
population experiencing HBV-sequelae based on Inter-
national Classification of Diseases 10th Revision (ICD-
10) at either a primary or secondary diagnosis code. The 
ICD-10 codes utilized in this study and the operational 
definitions are summarized to Appendix 1. This analysis 
using NHICD was approved by the Institutional Review 
Board of Seoul National University Hospital.
Direct non-medical costs of this study are composed 
of travelling cost, care-giving cost, and time cost, all of 
which requires information on healthcare utilization, 
such as the number of inpatient and outpatient visits, as 
well as hospitalization [39]. Thus, we analyzed the pat-
tern of healthcare utilization among individuals diag-
nosed with HBV-sequelae from NHICD (Table  3). The 
Table 1 Estimates of prevalence, effectiveness of vaccine & antiviral prophylaxis, and coverage
HBsAg hepatitis B Surface Antigen, HBeAg hepatitis B envelope antigen, HepB1 hepatitis B birth dose, HBIG hepatitis B immune globulin, 24 h 24 hours, PSA 
probabilistic sensitivity analysis
Base-case value Range PSA distribution PSA parameters Source
Population and risk of perinatal infection (%)
 Total birth of 2014 435,435 – – – [16]
 Prevalence of HBsAg among pregnant women 2.45 1.7–3.2 Beta α = 41.61; β = 1656.92 [7]
 Prevalence of HBeAg among HBsAg(+) pregnant 
women
38.5 29.7–44.3 Beta α = 64.37; β = 109.6 [10]
 Prevalence of high viral load among HBeAg(+)  
pregnant women
80 60–100 Uniform low = 0.6; high = 1 [23]
HBeAg(+) pregnant women
 HepB1 + HBIG within 24 h of birth 6.4 5.5–29 Beta α = 6.96; β = 33.39 [10, 24–28, 30]
 HepB1 within 24 h of birth 33.8 21–43 Beta α = 22.7; β = 48.24 [26–28]
 No HepB1 within 24 h of birth 87.5 62.6–96.7 Beta α = 16.97; β = 4.34 [29]
HBeAg(−) pregnant women
 HepB1 + HBIG within 24 h of birth 1.4 0–3 Beta α = 3.93; β = 257.74 [10, 25, 27, 30, 31]
 HepB1 within 24 h of birth 6.6 0–13.2 Beta α = 3.67; β = 51.94 [25, 27, 29]
 No HepB1 within 24 h of birth 13.2 2.6–46.2 Beta α = 3.54; β = 10.98 [29]
 Reduction in perinatal infection with antiviral prophy‑
laxis
50 37–85 Beta α = 9.47; β = 6.05 [32]
Coverage of interventions (%)
 Antiviral prophylaxis 100 50–100 Beta α = 8.25; β = 2.75 Assumed
 HepB1 + HBIG within 24 h of birth 99 85–100 Beta α = 44.71; β = 3.625 [10]
 HepB1 within 24 h of birth 90.7 46.4–92.3 Beta α = 10.5; β = 4.64 [33]
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same operational definition used for the cost analysis was 
applied uniformly for this investigation. We used differ-
ent travelling costs for hospital utilization, reflecting that 
the mode of transportation may differ between inpatient 
and outpatient visits [33, 39]. Additionally, the care-giv-
ing cost was the daily salary for a professional care-giver 
during hospitalization, which was obtained from the 
Korea Health Panel [39]. To calculate the time cost, we 
estimated the cost of labor loss during outpatient visits 
by using both the employment rate and average hourly 
payment [43].
Health outcome measures
We evaluated the effectiveness of this study by QALYs, as 
well as new cases of HBV-related morbidity and the dis-
ease specific mortality. QALY estimates of HBV-sequelae 
were adopted from the study of utility weights for major 
liver diseases in Korea as well as several economic evalua-
tion studies [44–47]. Following the recommendation of the 
Health Insurance Review & Assessment Service in Korea, 
both costs and QALYs were discounted at 5% [48]. The esti-
mates of utilities and discount rate are presented in Table 3.
Results
The results of cost-effectiveness analysis in this study are 
presented as incremental cost-effectiveness ratio (ICER), 
incidental cases of chronic hepatitis, compensated and 
decompensated cirrhosis, HCC, and HBV-related deaths. 
ICER is the difference in costs between the reference 
and the comparative strategy, divided by the difference 
in their QALYs. New cases of HBV-sequelae over the 
lifetime of the 2014 birth cohort are derived from the 
Markov cohort analysis, presenting the outcomes by per 
100,000 people. The results are summarized in Tables 4 
and 5.
Considering that PHBPP, which is the current strategy 
for preventing perinatal HBV infection in Korea, was set 
as the reference, ICER of PHBPP with antiviral prophy-
laxis was $16,159. Universal vaccination, on the other 
hand, was dominated by the reference since the former 
strategy produced not only higher costs, but also less 
total QALYs than the latter strategy.
Regarding the new cases of HBV-sequelae per 100,000 
people, PHBPP with antiviral prophylaxis averted 34 
cases of chronic hepatitis, 4 cases of compensated 
Table 2 Transition probabilities for each cycle of the markov model (Unit: %)
HCC hepatocellular carcinoma, PSA probabilistic sensitivity analysis
Base-case value Range PSA distribution PSA parameters Source
Perinatal infection to
 Immune tolerance/inactive state 89 80–90 Beta α = 172.55; β = 30.45 [20, 35]
Immune tolerance/Inactive state to
 Chronic hepatitis (years)
  < 25 0.43 0.3–0.65 Beta α = 29.32; β = 6144.29 [19]
  ≥ 25 3 2.9–7.3 Beta α = 20.35; β = 378.64 [19]
 Chronic hepatitis to
 Immune tolerance/inactive state 
(years)
  < 25 9 0–16.3 Beta α = 3.59; β = 40.49 [19]
  ≥ 25 10 8.3–16.3 Beta α = 33.05; β = 235.63 [19]
 Compensated cirrhosis (years)
  < 25 0.065 0.01–0.12 Beta α = 5.58; β = 8582.87 [19]
  ≥ 25 1.5 1–5.7 Beta α = 7.82; β = 225.69 [19]
  HCC 0.5 0.2–1 Beta α = 8.94; β = 1481.06 [20, 36]
  Disease‑related death 0.9 0.3–3.6 Beta α = 5.46; β = 274.46 [20, 36]
 Compensated cirrhosis to
  Decompensated cirrhosis 5.4 2.8–15 Beta α = 7.67; β = 78.49 [20, 36]
  HCC 3.3 0.5–6.6 Beta α = 5.19; β = 141.04 [20, 36]
  Disease‑related death 3.5 0–8 Beta α = 3.8; β = 91.2 [17, 20]
 Decompensated cirrhosis to
  HCC 7.1 0.15–10 Beta α = 3.98; β = 74.46 [17, 20, 36]
  Disease‑related death 15 9.9–50 Dirichlet List (20;75;5) [20, 36]
 HCC to
  Disease‑related death 54 8.1–70 Dirichlet List (20;75;5) [20, 36]
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HCC hepatocellular carcinoma, PHBPP Perinatal Hepatitis B Prevention Program, PSA probabilistic sensitivity analysis
Table 3 Estimates of cost parameters, utility, and discount rate
Base-case value Range PSA distribution PSA parameters Source
Annual expenditure by the government (USD)
 Budget of PHBPP in 2014 1,634,281 – – – [33]
 HBV vaccine per capita 60 48–72 Uniform low = 48; high = 72 [9]
 Antiviral prophylaxis per capita 369 178–559 Uniform low = 178; high = 559 [40]
 HBV‑DNA testing per capita 66 53–79 Uniform low = 53; high = 57 [41]
Direct medical cost per capita (USD)
 Chronic hepatitis
  Inpatient 248 ± 20% Gamma α = 0.0167; λ = 0.0001 –
  Outpatient 415 ± 20% Gamma α = 0.134; λ = 0.0032 –
  Pharmaceuticals 157 ± 20% Gamma α = 0.09; λ = 0.00058 –
 Compensated cirrhosis
  Inpatient 1504 ± 20% Gamma α = 0.034; λ = 0.00002 –
  Outpatient 473 ± 20% Gamma α = 0.11; λ = 0.00023 –
  Pharmaceuticals 125 ± 20% Gamma α = 0.119; λ = 0.00095 –
 Decompensated cirrhosis
  Inpatient 2602 ± 20% Gamma α = 0.236; λ = 0.00009 –
  Outpatient 189 ± 20% Gamma α = 0.336; λ = 0.00178 –
  Pharmaceuticals 53 ± 20% Gamma α = 0.106; λ = 0.00199 –
 HCC
  Inpatient 5161 ± 20% Gamma α = 0.232; λ = 0.00005 –
  Outpatient 1108 ± 20% Gamma α = 0.217; λ = 0.0002 –
  Pharmaceuticals 230 ± 20% Gamma α = 0.096; λ = 0.00042 –
 Direct non‑medical cost (USD)
  Transportation cost (inpatient) 25 ± 20% Uniform low = 20; high = 30 [33, 39]
  Transportation cost (outpatient) 5 ± 20% Uniform low = 4; high = 6 [33, 39]
 Average number of inpatient visit
  Chronic hepatitis 0.07 0–0.14 Gamma α = 0.027; λ = 0.379 –
  Compensated cirrhosis 0.29 0–0.58 Gamma α = 0.076; λ = 0.263 –
  Decompensated cirrhosis 0.54 0–1.08 Gamma α = 0.298; λ = 0.551 –
  HCC 1.53 0–3.06 Gamma α = 0.366; λ = 0.239 –
 Average number of outpatient visit
  Chronic hepatitis 4.19 0–8.38 Gamma α = 0.705; λ = 0.168 –
  Compensated cirrhosis 4.62 0–9.24 Gamma α = 0.847; λ = 0.183 –
  Decompensated cirrhosis 2.38 0–4.76 Gamma α = 0.442; λ = 0.186 –
  HCC 8.38 0–16.76 Gamma α = 0.704; λ = 0.084 –
  Daily cost of caregiving (USD) 59 ± 20% Uniform low = 47; high = 71 [33, 39]
 Average days of hospitalization
  Chronic hepatitis 0.61 0–1.22 Gamma α = 0.01; λ = 0.0168 –
  Compensated cirrhosis 3.81 0–7.62 Gamma α = 0.034; λ = 0.009 –
  Decompensated cirrhosis 6.33 0–12.66 Gamma α = 0.112; λ = 0.018 –
  HCC 15.63 0–31.26 Gamma α = 0.2102; λ = 0.0134 –
  Average hours spending on outpatient visit 2 1–3 Uniform low = 1; high = 3 [33, 39]
 Utility
  Immune tolerance/inactive state 1 – – –
   Chronic hepatitis 0.73 0.63–0.98 Beta α = 15.7; β = 3.803 [44–47]
   Compensated cirrhosis 0.65 0.35–0.95 Beta α = 5.92; β = 3.19 [44–47]
   Decompensated cirrhosis 0.46 0.25–0.75 Beta α = 7.5; β = 7.5 [44–47]
   HCC 0.46 0.16–0.75 Beta α = 4.73; β = 5.67 [44–47]
   Discount rate (%) 5 3–7 – – [48]
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cirrhosis, and 13 cases of HBV-related deaths per 100,000 
people over the lifetime compared with the reference.
To assess the robustness of the results, we conducted 
both deterministic and probabilistic sensitivity analyses. 
All parameters in this study were evaluated using a series 
of one-way sensitivity analyses, and the eight parameters 
showing a large variation of ICER were presented in the 
tornado diagram comparing PHBPP with antiviral proph-
ylaxis to current PHBPP (Fig. 3). Moreover, we attempted 
to assess their threshold when setting the willingness-to-
pay (WTP) to $29,000/QALY, a gross domestic product 
per capita in Korea during the year 2014 [43]. The results 
indicated that the discount rate of higher than 6.33% may 
affect robustness of the outcome. To further understand 
the impact of the discount rate on the ICER, we pre-
sented results under two different discounting scenarios 
(Appendix 2): (A) no discount rate was applied to both 
costs and QALYs, and (B) a lower discount rate was used 
for QALYs (2.5%) than for costs (5%). The results demon-
strated that PHBPP with antiviral prophylaxis in Scenario 
A was cost-saving, and the ICER of this strategy in Sce-
nario B was $4,926 compared to current PHBPP.
Table 4 Costs, QALYs, and ICER of three intervention strategies
PHBPP Perinatal Hepatitis B Prevention Program, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio
Costs (USD) Incremental costs QALYs Incremental QALYs ICER
PHBPP (reference) 28,236,374 – 8,462,686 – –
PHBPP with antiviral prophylaxis 29,561,401 1,325,027 8,462,768 82 16,159
Universal vaccination 29,312,011 1,075,637 8,461,656 − 1030 (Dominated)
Table 5 New cases of HBV-related diseases and deaths per 100,000 people
HCC hepatocellular carcinoma
Chronic hepatitis Compensated cirrhosis Decompensated cirrhosis HCC HBV-related deaths
PHBPP (reference) 106 12 0 0 13
PHBPP with antiviral prophylaxis 72 8 0 0 0
Universal vaccination 567 56 22 37 97
Fig. 3 Tornado diagram presenting one‑way sensitivity analyses (PHBPP with antiviral prophylaxis vs. current PHBPP). HBeAg, Hepatitis B Envelope 
Antigen; HepB1, Hepatitis B Birth Dose; HBIG, Hepatitis B Immune Globulin; QALY, quality‑adjusted life years
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The result of probabilistic sensitivity analysis (i.e. 
Monte Carlo Simulation using 100,000 iterations) is 
presented as the cost-effectiveness acceptability curve 
(CEAC) in Fig. 4, indicating the probability of cost-effec-
tiveness through a variation of WTP. The results showed 
that among the three preventive strategies against perina-
tal HBV infection, PHBPP with antiviral prophylaxis had 
approximately a 85% chance to be cost-effective when 
WTP for an additional QALY was over $20,000.
Discussion
This study demonstrated that PHBPP with antiviral 
prophylaxis for women with a high viral load of HBV 
(≥  106  copies/mL) during pregnancy may increase the 
quality of life and prevent HBV-related deaths in new-
borns when compared with PHBPP without antiviral 
prophylaxis. Moreover, this study showed that the anti-
viral prophylaxis intervention may be cost-effective from 
a healthcare system perspective according to WTP in the 
Korean society. The result is sensitive to one factor, indi-
cating that PHBPP with antiviral prophylaxis may not be 
cost-effective if the discount rate exceeds 6.33%. This well 
explains the effect of discounting on the cost-effectiveness 
of prevention programs where most costs occur early in 
the programs and most health benefits are realized in the 
future [49]. In this case, the ICER becomes less favorable 
as a higher discount rate is applied. Thus, to incorporate 
the value of future health benefits into decision making, 
adopting differential discounting could be considered as 
shown in Appendix 2 [50]. Our study also evaluated the 
cost-effectiveness of the current PHBPP compared with 
universal vaccination; the results showed that PHBPP may 
be superior with respect to cost-effectiveness.
If the provision of antiviral prophylaxis is incorporated, 
it appears that there could be a significant reduction in 
the economic and disease burden of HBV-related dis-
eases in Korea. Since high mortality and morbidity of 
liver diseases are mostly associated with an economi-
cally active population, a large proportion–84.4%–of 
economic burden stemmed from premature death and 
absence from work; the total cost was estimated to be 
about $5401 million in 2008 [51]. Moreover, the country’s 
burden of liver diseases is not negligible in that cirrhosis 
and HCC are ranked 3rd and 10th among males, and 8th 
and 45th among females by disability-adjusted life years 
(DALYs) [52]. Given that HBV infection is the primary 
cause of liver diseases in Korea, an alternative strategy 
that supplies antiviral prophylaxis to women with HBV 
during pregnancy may promote health and productivity 
of the overall population in Korea by preventing perinatal 
HBV infection.
Currently, economic evaluations of antiviral prophy-
laxis as a means to prevent vertical transmission of HBV 
have been implemented in several countries, including 
the United States (U.S), Taiwan, and China [15, 53, 54]. 
These evaluations suggest that an incorporation of antivi-
ral prophylaxis to the existing immunoprophylaxis strat-
egy against perinatal HBV infection can be cost-effective, 
corresponding to our analysis. Although these studies 
showed a large variation in the prevalence of HBsAg in 
pregnant women (from 0.6% of the U.S to 9.5% of Tai-
wan), the robustness of outcomes was not susceptible 
to the epidemiological status of HBsAg in each society. 
This may improve the decision-making process regarding 
the introduction of antiviral therapy to women who are 
HBsAg-positive during their late pregnancy.
This study has several limitations to consider. Our 
model did not take into account the risk of adverse events 
following antiviral prophylaxis during pregnancy. How-
ever, numerous literature support that antiviral agents, 
such as Lamivudine, Telbivudine, and Tenofovir, hardly 
yield any medical complications, like birth defects [54]. 
Furthermore, it was challenging to estimate the direct 
medical costs per capita using NHICD, considering 
that a high proportion of medical services for liver dis-
eases is not entirely covered by NHIS [55]. To address 
this, we applied the proportion of insurance coverage of 
HBV-sequelae, which Yang et al. obtained by investigat-
ing the medical records of patients with HBV-sequelae 
in 2006 from four tertiary hospitals in Korea (Appendix 
3), to acquire the total amount of direct medical costs 
in 2006 consisting of NHIS payment and out-of-pocket 
payment by an individual patient with HBV-sequelae 
[55]. The costs of 2006 were inflated to the value of 2014 
with an application of price index of inpatient, outpa-
tient, and pharmaceuticals [56, 57]. Moreover, because 
some parameters in the model, such as transition prob-
abilities of HBV-sequelae, were adopted from economic 
Fig. 4 Cost‑effectiveness acceptability curve. PHBPP, Perinatal 
Hepatitis B Prevention Program; HepB, Hepatitis B Vaccination; QALY, 
quality‑adjusted life years
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evaluation studies performed in other countries, the 
result of our study may not be perfectly applicable to 
the Korean health system. By implementing sensitiv-
ity analysis, however, we tried to advocate robustness of 
the results in this study. Lastly, since the time horizon 
of our model was the entire lifespan of the 2014 birth 
cohort, the projected outcomes reported as a net present 
value in this study may not support decision making for 
budget planning. This is because budgeting requires pre-
cise estimates of costs and outcomes in accordance with 
relevant time horizons of budget holders which is nor-
mally 1–5 years [58]. An additional budget impact analy-
sis of introducing antiviral prophylaxis during pregnancy 
needs to be implemented to illustrate financial flows for 
each budget period after the onset of the intervention.
Conclusions
This study implies that in Korea, PHBPP with antiviral 
prophylaxis may be the most cost-effective strategy under 
WTP of $29,000/QALY, and that this strategy is likely 
effective in reducing the burden of liver diseases by pre-
venting mother-to-child transmission of HBV. Therefore, 
it is advisable to augment the current PHBPP in Korea by 
supplying antiviral therapy to women with a high viral load 
of HBV (≥ 106 copies/mL) during their late pregnancy.
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Appendix 1. Operational definitions of HBV-related 
diseases
Disease category Operational definition (ICD-10)
Chronic hepatitis Contains B18 at a primary or sec‑
ondary diagnosis code, and does 
not contain K74, C22 at a primary 
or secondary diagnosis code
Compensated cirrhosis Contains K74 at a primary or sec‑
ondary diagnosis code, and does 
not contain I85, K65, R18, R60, 
R17, K76.6, K76.7 at a primary or 
secondary diagnosis code
Decompensated cirrhosis Contains K74 at a primary or sec‑
ondary diagnosis code, and con‑
tains I85, K65, R18, R60, R17, K76.6, 
K76.7 at a primary or secondary 
diagnosis code
Hepatocellular carcinoma Contains C22 at a primary or 
secondary diagnosis code, and 
contains V027, V193, V194 at a 
cancer confirmation code
Appendix 2. Results of cost-effectiveness analysis 




















54,929,313 22,593,113 35,599,124 − 14,632 (Domi‑
nated)












29,312,011 1,075,637 14,914,601 − 3407 (Domi‑
nated)
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Appendix 3. Proportion of insurance benefit 
coverage for HBV-related diseases
Inpatient Outpatient Pharmaceuticals
Chronic hepatitis 0.35 0.50 0.46
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